Assembly Biosciences Inc logo

Assembly Biosciences Inc(ASMB)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$21.12
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for ASMB

11/13/2026: ASMB (1-star) is currently NOT-A-BUY. Pass it for now.

Assembly Biosciences is a clinical-stage biotechnology company focused on developing innovative antiviral therapeutics for serious viral infections like herpesviruses and hepatitis delta virus. The company's primary strengths include a specialized scientific platform and a strategic research partnership with Gilead Sciences that supports its financial runway. Its main growth opportunity centers on advancing clinical candidates such as ABI-5366 through key trial milestones. Key risks include heavy dependence on successful clinical outcomes, regulatory hurdles, and intense competition in the antiviral space. The stock suits high-risk growth investors willing to monitor upcoming clinical data readouts and partnership developments.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorMixed fitThe company offers long-term clinical pipeline expansion potential but lacks near-term commercial revenue growth.
Momentum investorStrong fit while signal remains positiveClinical data readouts and partnership developments frequently drive sharp short-term momentum shifts in the stock.
Value investorWeak fitAs a pre-revenue clinical-stage biotech firm, traditional value metrics like P/E ratios are inapplicable.
Dividend investorWeak fitThe company does not pay dividends and retains all capital to fund ongoing research and clinical trials.
Low-risk investorWeak fitClinical-stage biotechnology stocks carry high binary risks related to clinical trials and regulatory approvals.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighClinical trial results and regulatory updates can trigger significant stock price swings.
Valuation riskMedium / highValuation relies heavily on subjective clinical pipeline projections rather than current earnings.
Competition risk (viral therapeutics competition)Medium / highRival biotechnology and pharmaceutical companies are actively developing alternative antiviral treatments.
Business qualityMediumThe company possesses strong scientific expertise and major partnerships, but lacks commercial operations.
Dividend incomeLow / noneNo dividend is paid to investors.
Execution riskHighSuccess depends entirely on safely and effectively advancing complex clinical trials through regulatory approval.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 432.48M USD
Price to earnings Ratio 28.16
1Y Target Price 51.2
Price to earnings Ratio 28.16
1Y Target Price 51.2
Volume (30-day avg) 241.8K shares
Beta 1.22
52 Weeks Range 19.20 - 39.71
Updated Date 11/15/2026
52 Weeks Range 19.20 - 39.71
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) 0.75

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Biotechnology

BUY participation
45.5%
Active BUY / eligible
20 / 44
30-Day BUY Count Change
+13

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Downtrend
PRICE PATH

Downtrend

The stock has experienced a sustained decline in price over recent periods.

Choppy
PRICE STABILITY

Choppy

The stock has experienced frequent reversals and pronounced short-term price swings.

Analysis of Past Performance

Type Stock
Historic Profit 47.84%
Avg. Invested days 32
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 3.0
Stock Returns Performance Upturn Returns Performance icon 3.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
ASMB receives a 3-star rating, supported by solid company fundamentals, and solid analyst coverage. The rating is constrained by weak unit economics, soft quantitative characteristics, and weak price momentum.

Company Fundamentals

★★★★★
ASMB has solid overall fundamentals (4 stars), with moderate financial health, strong growth momentum, and strong ownership. In FY2025 versus FY2024, strong earnings growth (+84.8%) and strong revenue growth (+153.5%) are partially offset by weak cash generation (FCF margin -56.9%), weak profitability (net margin -8.5%).

Financial Health Rating

★★★★★
ASMB's financial health is supported by moderate liquidity, including working-capital and asset support (WC/assets 79.9%). Cash strength is soft (2 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
Revenue growth is ASMB's strongest growth driver at +153.5% FY2025 versus FY2024 (strong, 5 stars). Earnings growth (+84.8%, strong) and free-cash-flow growth (+19.5%, solid) are also constructive, though not equally high across every growth measure.

Ownership

★★★★★
Institutional ownership is 76.8% and approximately 50.2% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 27.99% supports management-shareholder alignment.

Top 5 Institutional Investors

Farallon Capital Management, L.L.C. 7.88%
Paradigm Biocapital Advisors LP 7.63%
COMMODORE CAPITAL LP 6.95%
RA Capital Management, LLC 5.01%
Jupiter Topco LLC 4.17%

Unit Economics (Per $1K Revenue)

★★★★★
ASMB generates approximately $998 of gross profit, $-168 of operating income, and $-569 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Operating losses and cash burn explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 0.00%

Quantitative Style Profile

★★★★★
ASMB has a liquid profile. Weak momentum is the primary drawback, while valuation that is moderately attractive rather than deeply discounted.

Style Classification

Quality Focused

High VolatilitySmall / Mid Cap RiskShort Squeeze RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Collaboration and Research RevenueUpfront payments, research funding, and potential milestone payments derived from strategic research partnerships like the agreement with Gilead Sciences.The company currently operates at a loss, funding its drug development pipeline primarily through partner support and equity financing rather than commercial product sales.

Valuation

Trailing PE 28.16
Forward PE 416.67
Enterprise Value 120.83M
Price to Sales(TTM) 6.45
Enterprise Value 120.83M
Price to Sales(TTM) 6.45
Enterprise Value to Revenue 1.8
Enterprise Value to EBITDA 0.42
Shares Outstanding 20.48M
Shares Floating 10.28M
Shares Outstanding 20.48M
Shares Floating 10.28M
Percent Insiders 27.99
Percent Institutions 76.83

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.